For hemodialysis patients with iron-deficiency anemia, ferumoxytol presents no greater short-term risks than other commonly used intravenous (IV) iron formulations, a new study confirms.
Using the United States Renal Data System, Wolfgang C. Winkelmayer, MD, of Baylor College of Medicine in Houston, and colleagues identified 265 hemodialysis centers that switched to ferumoxytol and matched each to 3 clinics that continued to use iron sucrose or sodium ferric gluconate. The investigators then determined rates of infection, cardiovascular events, and early death among patient groups subsequently starting hemodialysis at these facilities.
Of 14,206 patients, 3,752 received ferumoxytol and 10,454 received iron sucrose or sodium ferric gluconate. Patient characteristics were similar between groups to start. The average doses of iron and erythropoiesis-stimulating agent and the achieved hemoglobin concentration also were comparable.
According to results published online in Nephrology Dialysis Transplantation, the odds of mortality over roughly 2 years were similar between the groups, including death from cardiovascular disease, infection, or any cause. When the investigators examined a subgroup of 5,513 Medicare beneficiaries, they also found no meaningful differences in non-fatal events, including myocardial infarction, stroke, cardiovascular death, and serious infection.
The authors concluded that in the typical hemodialysis care setting, ferumoxytol possesses similar short- to mid-term safety profiles, the investigators stated. The results corroborate general findings from previous trials, which included too few participants to find statistically significant differences.
Among the limitations, the researchers were unable to examine ferritin levels, transferrin saturation, and the occurrence of anaphylactoid reactions.